Oxford, UK – 5 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new License and Supply Agreement (LSA) with Cabaletta Bio, Inc. (Nasdaq: CABA) (“Cabaletta Bio”), a Philadelphia, USA-based clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The LSA grants Cabaletta Bio a non-exclusive license to Oxford Biomedica’s LentiVector® platform for its application in Cabaletta Bio’s leading Chimeric AutoAntibody Receptor (CAAR) T programme, DSG3-CAART (targeting DSG3), and puts in place a multi-year Supply Agreement. The financial arrangements of this LSA are in line with comparable deals the Group has previously secured.
Cabaletta Bio’s DSG3-CAART product candidate utilises Cabaletta’s CAAR T approach, in which the patient’s own T cells are genetically engineered to express the target autoantigen and direct them to recognise and eliminate the pathogenic B cells. DSG3-CAART is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris (mPV), a prototypical B cell-mediated autoimmune disease. The LSA also allows for the parties to initiate additional projects in the future.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “Cabaletta Bio is one of the leading companies developing engineered T cells designed to treat patients with autoimmune diseases. We are delighted to announce this new collaboration which strengthens our portfolio of relationships with leaders in the gene-modified cell therapy field.”
Gwendolyn Binder, Ph.D., EVP of Science and Technology, Cabaletta Bio, said: “Oxford Biomedica’s LentiVector® platform technology is well established with regulators, and we are impressed by their continuous process improvements, GMP manufacturing and validation expertise. We are very pleased to be working with them to support the clinical and commercial development of our DSG3-CAART program.”
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: email@example.com
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim and Arcellx, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com